Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643885 · ClinicalTrials.gov registry record
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 7,304
- Enrollment target
NCT05643885: Completed study, sponsored by Pfizer.
NCT05643885 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7,304 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05643885 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 7,304 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
Primary Outcome
The all-cause healthcare cost for VTE event was defined as the sum of total cost associated with the total inpatient, total outpatient, and total pharmacy costs for the VTE event. Costs were converted to 2021 United States dollars (USD) using the medical component of the consumer price index and was expressed as cost per participant per month. The date of the first apixaban or LMWH prescription on or within the 30 days following a VTE diagnosis was considered as the index date.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,304 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2024-08-30 |
What the finished NCT05643885 record still lists
NCT05643885 is an observational study that tracks outcomes without assigning an intervention. Its 7,304 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05643885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05643885 about?
NCT05643885 is a clinical study titled "A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer". The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause co...
What is the current status of trial NCT05643885?
This trial is currently completed. The enrollment target is 7,304 participants. The study started on 2022-08-31. Estimated completion is 2024-08-30.
Who is sponsoring clinical trial NCT05643885?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI